York University spinout Pro-Cure Therapeutics has received a further £150,000 from the White Rose Technology Seedcorn Fund to develop therapies for prostate cancer – the second most common cause of cancer death among males.

York University spinout Pro-Cure Therapeutics has received a further £150,000 from the White Rose Technology Seedcorn Fund to develop therapies for prostate cancer – the second most common cause of cancer death among males.

The gene therapy specialist, which was established two years ago by the same venture capital fund, has signed two research contracts this year.

Richard Lane, partner and head of the Corporate team at Farrer & Co, led the team acting as legal counsel for the Fund.

The White Rose Technology Seedcorn Fund is owned by Leeds, Sheffield and York Universities. It was formed with £4.5 million from the DTI, but this now stands at £9 million following further investment from the member universities and regional development agency Yorkshire Forward.